Quest Diagnostics announces acquisition of Blueprint Genetics
Category: #health  By Mateen Dalal  Date: 2020-01-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

Quest Diagnostics announces acquisition of Blueprint Genetics

Quest Diagnostics announced the acquisition of genetic testing firm, Blueprint Genetics to extend access to actionable insights in genetic and rare diseases. The acquisition is aimed at enhancing patient care and boosting research and development of pharmaceutical drugs. The deal is an all-cash equity transaction, but financial terms of the transaction have not been disclosed yet.

Blueprint Genetics has recently launched a hub facility in Seattle, Washington to expand its footprints in the United States. It is expected that Blueprint Genetics will mostly operate independently from its base laboratory situated in Helsinki, Finland and a presence in several other nations.

Steve Rusckowski, the CEO, Chairman, and President, Quest Diagnostics, reportedly stated that it is a great task to generate quality, actionable, and broadly accessible insights from a large quantity of sequenced genetic data with genetic testing. The acquisition of Blueprint Genetics will help the company to strengthen and extend its value proposition in genetics to provide accelerated growth strategy and offer a visualization of a healthier world.

The acquisition is expected to generate new capabilities for serving suppliers focusing on rare disease and neurology, especially academic and pediatric hospitals. Quest and Blueprint Genetics also expect that the acquisition will offer benefits to the members of Quest Diagnostics Global Diagnostic Network and its in-vitro and pharmaceutical diagnostic partners. Quest will leverage high-touch service of Blueprint Genetics in variant interpretation & reporting and related sequencing and bioinformatics to complement and develop its current genetics leadership.

For the record, genetic testing is helpful in diagnosis of several rare disorders and identification of potential risks of treatment for certain cancers and other conditions. As per the National Institutes of Health, existence of around 7,000 rare diseases has been recorded and about 30 million Americans are enduring a rare disease.

 

Source links:

https://newsroom.questdiagnostics.com/2020-01-22-Quest-Diagnostics-Acquires-Blueprint-Genetics-to-Broaden-Access-to-Actionable-Insights-for-Genetic-and-Rare-Diseases

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

DealerSocket closes acquisition of Auto/Mate to offer innovative DMS
DealerSocket closes acquisition of Auto/Mate to offer innovative DMS
By Mateen Dalal

DealerSocket, a customer relationship management solutions provider, has recently completed the acquisition of DMS provider Auto/Mate to offer an all-in-one innovative software for their dealerships. Auto/Mate is a leading company that develops and m...

EU and U.S. to partner to counter Huawei’s dominance on next-gen 5G
EU and U.S. to partner to counter Huawei’s dominance on next-gen 5G
By Mateen Dalal

The European Union and the United States are likely to partner to counter the increasing dominance of Chinese tech giant, Huawei Technologies on next generation 5G telecommunications technology. However, this partnership will reportedly only come int...

CytoDyn files Phase 2 basket trial for cancer antagonist Leronlimab
CytoDyn files Phase 2 basket trial for cancer antagonist Leronlimab
By Mateen Dalal

CytoDyn Inc., announced that it has submitted a Phase 2 protocol with the U.S. Food and Drug Administration (FDA) for a basket trial under its cancer IND. The company can instantly start enrollment in this trial to offer therapy for around 22 various...